Home' Australian Pharmacist : Australian Pharmacist January 2017 Contents Australian Pharmacist January 2017 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
THE COMPLEMENTARY APPROACH
1. Which of the following is considered
first-line treatment for persistent sleep
a) Concentrated valerian 600 mg daily taken
for at least 1 week.
b) A combination of valerian, passionflower
c) A benzodiazepine taken for 1 month.
d) Non-pharmacological approaches
such as cognitive behavioural therapy,
sleep hygiene and stress management
2. What advice might you give to a person
experiencing disrupted sleep patterns
with regard to the effects of light/dark
cycles on sleep?
a) Attempt to ensure exposure to sunlight
during the day and limit exposure to light
(especially light at the warmer end of the
colour spectrum) before bedtime.
b) Attempt to ensure exposure to light in the
early evening and limit exposure to blue
light in the morning.
c) Attempt to ensure exposure to light
during the day and limit exposure to light
(especially blue light) before bedtime.
d) Attempt to ensure exposure to blue light in
the evening and limit exposure to light at
the warmer end of the colour spectrum in
3. Which of the following statements
about people experiencing insomnia
describes the MOST suitable candidate
for a therapeutic trial with kava?
a) A person with alcohol dependence who is
unable to take pharmaceutical hypnotics
due to hepatic impairment.
b) A person who experiences mild-to-
moderate anxiety that affects their sleep,
but does not wish to take pharmaceutical
c) A person who is unable to take
pharmaceutical hypnotics due to positive
hepatitis C status.
d) A person who has Parkinson’s disease.
4. Why might relaxation techniques be
recommended as part of an overall
strategy to assist people with persistent
a) Relaxation techniques may assist with
stress reduction and emotional regulation.
b) Relaxation techniques cause drowsiness
and sedation, so if practised before bed,
they can have a beneficial effect on sleep.
c) Relaxation techniques practised in the
middle of the day play an important role
in controlling periodic circadian (24-hour)
d) Relaxation techniques should be avoided
by people who experience sleep disorders
as they can cause drowsiness.
Non-ingestive interventions such as CBT, sleep hygiene education and
stress management techniques should be recommended as first-line
treatments for insomnia and can be used safely as an adjunct to other
A therapeutic trial of herbal medicines such as sour cherry, valerian, kava
or passionflower may be warranted for those unable or unwilling to take
1. Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest
2. Sarris J, Byrne GJ. A systematic review of insomnia and complementary
medicine. Sleep Med Rev 2011;15(2):99–106.
3. Combs D, Goodwin JL, Quan SF, et al. Insomnia, health-related quality of life
and health outcomes in children: a seven year longitudinal cohort. Scientific
4. Castro-Diehl C, Diez Roux AV, Redline S, et al. Association of sleep duration
and quality with alterations in the hypothalamic-pituitary adrenocortical axis:
the multi-ethnic study of atherosclerosis (MESA). J Clin Endocrinol Metab
5. Anderson GD, Elmer GW, Taibi DM, et al. Pharmacokinetics of valerenic acid
after single and multiple doses of valerian in older women. Phytother Res
6. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and
complementary and alternative medicine: Analysis of the 2002 national health
interview survey data. Arch Intern Med 2006;166(16):1775–82.
7. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in
cancer care. Integr Cancer Ther 2004;3(2):128–48.
8. Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep
medicines in older adults. Clinical therapeutics 2016.
9. Trauer JM, Qian MY, Doyle JS, et al. Cognitive behavioral therapy for chronic
insomnia: a systematic review and meta-analysis. Ann Internal Med
10. Wu JQ, Appleman ER, Salazar RD, et al. Cognitive behavioral therapy for
insomnia comorbid with psychiatric and medical conditions: a meta-analysis.
JAMA Intern Med 2015;175(9):1461–72.
11. Morawetz D. Insomnia and depression: which comes first? Sleep Research
KEY LEARNING POINTS
12. Morawetz D. Sleep better without drugs: a 4-to-6 week self-help program.
Melbourne, Australia. 2016. At: www.sleepbetter.com.au
13. Rahimi A, Ahmadpanah M, Shamsaei F, et al. Effect of adjuvant sleep hygiene
psychoeducation and lorazepam on depression and sleep quality in patients
with major depressive disorders: results from a randomized three-arm
intervention. Neuropsychiatr Dis Treat 2016;12:1507–15.
14. Lack LC, Wright HR. Treating chronobiological components of chronic
insomnia. Sleep Med 2007;8(6):637–44 .
15. Gringras P, Middleton B, Skene DJ, et al. Bigger, brighter, bluer-better? current
light-emitting devices - adverse sleep properties and preventative strategies.
Front Public Health 2015;3:233.
16. Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences
and effective treatment. Med J Aust 2013;199(8):36–40.
17. Ong JC, Manber R, Segal Z, et al. A randomized controlled trial of mindfulness
meditation for chronic insomnia. Sleep 2014;37(9):1553–63 .
18. Zeidan F, Emerson NM, Farris SR, et al. Mindfulness meditation-based pain relief
employs different neural mechanisms than placebo and sham mindfulness
meditation-induced analgesia. J Neurosci 2015;35(46):15307–25 .
19. Black DS, O’Reilly GA, Olmstead R, et al. Mindfulness meditation and
improvement in sleep quality and daytime impairment among older adults
with sleep disturbances: a randomized clinical trial. JAMA Internal Med
20. Yurcheshen M, Seehuus M, Pigeon W. Updates on nutraceutical sleep
therapeutics and investigational research. Evid Based Complement Alternat
21. Pigeon WR, Carr M, Gorman C, et al. Effects of a tart cherry juice beverage
on the sleep of older adults with insomnia: a pilot study. J Med Food
22. Ziegler G, Ploch M, Miettinen-Baumann A, et al. Efficacy and tolerability of
valerian extract LI 156 compared with oxazepam in the treatment of non-
organic insomnia--a randomized, double-blind, comparative clinical study. Eur
J Med Res 2002;7(11):480–6 .
23. Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic
formulation NSF-3 in primary insomnia in comparison to zolpidem: a
randomized controlled trial. Indian J Pharmacol 2013;45(1):34–9 .
24. Taavoni S, Nazem Ekbatani N, Haghani H. Valerian/lemon balm use for sleep
disorders during menopause. Complement Ther Clin Pract 2013;19(4):193–6 .
25. Braun L, Cohen M. Herbs & natural supplements: an evidence based guide. 4th
edn. Sydney: Elsevier; 2015.
26. Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy,
safety, and psychopharmacology. Aust N Z J Psychiatry 2011;45(1):27–35.
27. Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated
with anxiety disorders. Results of a multicenter, randomized, placebo-controlled,
double-blind clinical trial. J Affect Disord 2004;78(2):101–10.
28. Sarris J, Stough C, Teschke R, et al. Kava for the treatment of generalized
anxiety disorder RCT: analysis of adverse reactions, liver function, addiction,
and sexual effects. Phytother Res 2013;27(11):1723–8 .
29. Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the
effects of passiflora incarnata (passionflower) herbal tea on subjective sleep
quality. Phytother Res 2011;25(8):1153–9 .
Each question has only one correct answer.
Links Archive Australian Pharmacist December2016 Navigation Previous Page Next Page